New data from ASCO26 reveals that GSK’s velzatinib demonstrates a compelling 61% response rate in patients with first-line gastrointestinal stromal tumors (GIST). Presented at the prestigious oncology conference, the early-stage trial findings highlight velzatinib’s potential as a highly effective therapeutic option for GIST, a rare and challenging cancer to treat. The trial included a diverse patient pool, indicating broad applicability across the GIST population. Researchers observed substantial tumor reduction in participants, underscoring the drug’s efficacy and bolstering hope for improved first-line treatments. GSK’s velzatinib could mark a significant step forward in GIST management, where treatment options have traditionally been limited. This breakthrough could pave the way for further studies and regulatory consideration, potentially offering a new lifeline for patients with this aggressive cancer. The promising response rate signals a potential paradigm shift in how GIST is approached within clinical settings.
FirstWord PharmaNew data shows alarming decline in tobacco tax revenue as black market surges, putting pressure on Labor
June 4, 2026
Recent revelations indicate a significant drop in tobacco tax revenues, with billions lost to the burgeoning black market, intensifying pressure on the Labor government in